<DOC>
	<DOCNO>NCT00527397</DOCNO>
	<brief_summary>Assess safety toleration CP-464,005 Inhaler follow 1-year ( 52 week ) administration Type 1 Type 2 diabetes patient ( non-smokers )</brief_summary>
	<brief_title>Long-Term Safety Study Of Inhaled Insulin ( CP-464,005 , Inhaler ) In Japanese Patients With Type1 Type2 Diabetes</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing CP-464,005 . At time recruitment study , A2171105 place hold . Nektar , company Pfizer license CP-464,005 , announce April 9 , 2008 stop search new marketing partner . As result , study A2171105 terminate April 10 , 2008 . Neither safety efficacy reason cause study termination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients diagnose Type 1 Type 2 diabetes least 1 year , base diagnostic criterion diabetes . Patients smoke 6 month prior screen ( smoke shall prohibit term study , well ) Patients exhibit pulmonary function test ( spirometry ) abnormality ( FVC FEV1 &lt; 70 % predict ) ) Week 4 .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Diabetes Mellitus</keyword>
</DOC>